Posted by Michael Wonder on 28 Mar 2026
Bepirovirsen accepted for review by the EMA as a potential first in class treatment for chronic hepatitis B
27 March 2026 - Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials.
GSK today announced that the EMA has accepted for review the marketing authorisation application for the use of bepirovirsen, an investigational antisense oligonucleotide, in the treatment of adults with chronic hepatitis B.
